Breaking Down Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Financial Health: Key Insights for Investors

Guangzhou Baiyunshan Pharmaceutical's latest figures paint a nuanced picture for investors: Q3 2025 operating revenue reached CNY 61.606 billion and TTM revenue through September stood at CNY 77.325 billion, while market capitalization sits near CNY 44.48 billion with a P/S of 0.52; profitability shows promise with net profit attributable rising 30.28% year‑on‑year in Q3 and TTM net income of CNY 3.26 billion (EPS CNY 2.01), yet margins are modest (operating margin 4.78%, profit margin 3.85%) even as ROE is 7.97% and dividend yield 4.60% (payout ratio 77.85%); balance sheet and liquidity metrics include cash and equivalents of CNY 11.827 billion, current ratio 1.60, quick ratio 1.15, debt/equity 0.40 and interest coverage 9.12, but rising concerns-net cash flow from operations plunged 162.45% in Q3 and debt/FCF is 16.16 while Altman Z‑Score is 2.43 and Piotroski F‑Score is 4-set against valuation multiples like P/E 13.46 and EV/EBITDA 8.96 and growth projections of roughly 6% EPS and 3.4% revenue annually; explore the detailed revenue, profitability, leverage, liquidity and valuation breakdowns ahead

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Revenue Analysis

• Q3 2025 operating revenue: CNY 61.606 billion (up 4.31% YoY)
• TTM revenue as of Sep 2025: CNY 77.325 billion (up 1.50% YoY)
• Q1 2025 revenue: CNY 22.47 billion; Q1 2025 net income: CNY 1.82 billion
• Full-year 2024 revenue: CNY 74.99 billion (down 0.69% YoY)
• Revenue per employee: CNY 3.09 million
• Market capitalization: approx. CNY 44.48 billion; P/S ratio: 0.52

Key revenue dynamics to watch include the translation of quarterly growth (Q3 2025 +4.31% YoY) into sustained TTM improvement (+1.50% YoY through Sep 2025) and whether margins evidenced in Q1 2025 net income (CNY 1.82 billion) can be maintained as full-year comparisons normalize. The revenue-per-employee metric (CNY 3.09 million) underscores operational leverage, while a market cap of ~CNY 44.48 billion and a P/S of 0.52 frame the stock's valuation context for investors assessing upside versus execution risk.

Additional context on corporate history, ownership, mission and business model can be found here: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited: History, Ownership, Mission, How It Works & Makes Money

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Profitability Metrics

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) reported solid year-over-year profit growth in Q3 2025, while key margins and shareholder returns indicate moderate profitability with a strong emphasis on dividend distribution. For broader corporate context and background, see Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited: History, Ownership, Mission, How It Works & Makes Money.

• Q3 2025 net profit attributable to shareholders: +30.28% vs Q3 2024.
• TTM net income (as of Sep 2025): CNY 3.26 billion; TTM EPS: CNY 2.01.
• Operating margin: 4.78%; Profit margin: 3.85% - indicating moderate operating efficiency.
• Return on equity (ROE): 7.97% - return generated on shareholders' equity.
• Earnings yield: 6.14% - earnings relative to current market price.
• Dividend yield: 4.60% with a payout ratio of 77.85% - sizable cash return to shareholders.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Debt vs. Equity Structure

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) shows a conservative leverage profile with solid liquidity and coverage metrics. Key capital-structure metrics and their immediate implications are summarized below.

• Debt-to-Equity: 0.40 - conservative leverage; equity base remains the dominant funding source.
• Current Ratio: 1.60 - adequate short-term asset buffer to cover liabilities.
• Quick Ratio: 1.15 - sufficient immediate liquidity excluding inventories.
• Interest Coverage Ratio: 9.12 - strong ability to service interest from operating earnings.
• Debt-to-EBITDA: 3.59 - moderate leverage relative to operating profit; not excessive but bears monitoring.
• Debt-to-Free Cash Flow: 16.16 - debt levels manageable relative to cash generation, though this ratio signals sensitivity to cash-flow volatility.

• Implications for investors: lower financial distress risk from modest leverage and high interest coverage, but monitor cash-flow variability given the elevated debt-to-FCF multiple.
• Areas to watch: changes in EBITDA, working capital swings, capital expenditure needs, and any shifts toward higher debt financing.
• Contextual reference: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited: History, Ownership, Mission, How It Works & Makes Money

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Liquidity and Solvency

• Cash and cash equivalents (June 2025): CNY 11.827 billion - a substantial liquidity buffer for near-term obligations and working capital needs.
• Total assets (FY 2024): CNY 81.68 billion - indicating a broad asset base to support operations and leverage capacity.
• Operating cash flow (last 12 months): CNY 2.43 billion - consistent cash generation from core operations.
• Free cash flow (last 12 months): CNY 1.09 billion - positive FCF, supporting reinvestment and potential deleveraging without reliance on external financing.
• Altman Z-Score: 2.43 - places the company in a moderate-risk zone for financial distress.
• Piotroski F-Score: 4 - reflects average financial strength and mixed signals on profitability, leverage, liquidity, and operating efficiency.

• Liquidity profile: ample cash reserves relative to near-term cash needs; positive operating and free cash flow support ongoing capital requirements.
• Solvency profile: a sizeable asset base offsets moderate Altman Z-Score; mixed Piotroski signals warrant monitoring of profitability and leverage trends.
• Investor considerations: track trends in operating cash flow conversion, capex levels affecting free cash flow, and any shifts in leverage that would move the Altman Z-Score or Piotroski F-Score materially.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Valuation Analysis

• EV/EBITDA: 8.96 - implies a moderate enterprise valuation relative to operating earnings.
• EV/FCF: 40.58 - indicates the market is pricing a premium relative to free cash flow, a possible signal of lower cash conversion or growth expectations.
• P/E: 13.46 - a reasonable price against reported earnings, often attractive in the pharmaceutical sector if earnings are stable.
• Book value per share: CNY 25.48 - a tangible NAV benchmark for assessing upside/downside versus market price.
• Market capitalization: ~CNY 44.48 billion with P/S of 0.52 - suggests the stock may be trading below one-times sales, a potential indicator of undervaluation.
• 52-week price change: +8.48% - reflects modest positive market sentiment over the past year.

• If earnings are durable, the P/E of 13.46 and EV/EBITDA of 8.96 support a value-oriented case.
• The high EV/FCF (40.58) warrants scrutiny of working capital, capex, and one-off cash items that depress free cash flow.
• Book value per share at CNY 25.48 vs. market price provides a tangible anchor for margin-of-safety assessments.
• P/S of 0.52 combined with a CNY 44.48 billion market cap suggests room for re-rating if growth or profitability improves.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Risk Factors

• Sharp deterioration in operating cash flow: net cash flow from operating activities fell by 162.45% in Q3 2025, indicating a swing from positive to sharply negative or a significant decline in cash-generating capacity.
• Moderate bankruptcy risk: Altman Z-Score of 2.43, which sits in the zone of moderate distress and warrants monitoring of solvency trends and near-term liquidity.
• Average fundamental strength: Piotroski F-Score of 4 suggests only average financial health and room for operational or accounting improvements to strengthen the firm's fundamentals.
• High leverage relative to cash generation: debt-to-free cash flow ratio of 16.16, implying substantial debt obligations compared with free cash flow available to service them.
• Thin profitability margins: operating margin of 4.78% and net profit margin of 3.85%, both relatively low and signaling limited buffer versus cost or revenue shocks.
• Valuation mixed signals: earnings yield of 6.14% and P/E ratio of 13.46 - potentially indicative of undervaluation, but possibly reflecting market skepticism about sustainability of earnings and cash flows.

• Short-term liquidity risk: the steep decline in operating cash flow combined with high debt-to-free cash flow raises the risk of near-term financing stress or covenant pressure if trends continue.
• Profitability vulnerability: low operating and net margins reduce flexibility to absorb rising input costs, pricing pressure, or declines in sales volume.
• Capital allocation and debt servicing: with debt sizable relative to free cash flow, management's ability to prioritize debt repayment, R&D, and capex becomes constrained.
• Market sentiment and valuation: a P/E of 13.46 and earnings yield of 6.14% may attract value-focused investors, but these metrics also reflect concern over earnings quality and sustainability given cash flow weakness.
• Operational execution risk: a Piotroski F-Score of 4 highlights potential weaknesses across profitability, leverage, liquidity, and operating efficiency that require remediation.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Growth Opportunities

• Analysts project earnings to grow by approximately 6% per annum, with revenue expected to increase by ~3.4% annually - consistent with a mature pharmaceutical manufacturer expanding through product mix, price and selective M&A.
• Total assets reached CNY 81.68 billion in 2024, providing scale for R&D, capacity expansion and potential acquisitions.
• Operating cash flow of CNY 2.43 billion over the last 12 months supports internal investment and dividend capacity.
• The company proposed a cash dividend of CNY 0.40 per share for 2024, signaling commitment to shareholder returns while retaining reinvestment firepower.
• Market capitalization is approximately CNY 44.48 billion, with a P/S ratio of 0.52 - suggesting potential undervaluation versus growth prospects.
• Long-term compounding: market capitalization has increased by about 1,150.74% since 2001, reflecting sustained value creation over decades.

• Key growth levers: leveraging CNY 81.68 billion asset base for capacity and R&D, converting CNY 2.43 billion operating cash flow into high-return projects, and deploying a balanced dividend policy (CNY 0.40/share) to maintain investor confidence.
• Valuation angle: with a P/S of 0.52 and market cap ~CNY 44.48 billion, the stock may offer upside if execution lifts earnings at the forecast 6% CAGR while revenue grows at ~3.4%.